scholarly journals Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina

Lupus ◽  
2020 ◽  
Vol 29 (11) ◽  
pp. 1385-1396 ◽  
Author(s):  
A Babini ◽  
A M Cappuccio ◽  
C Caprarulo ◽  
G Casado ◽  
A Eimon ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Real World ◽  
Lupus Erythematosus ◽  
Clinical Effectiveness ◽  
Physician Global Assessment ◽  
Systemic Lupus ◽  
Corticosteroid Dose ◽  
Clinical Practice Setting ◽  
Secondary Endpoints ◽  
Dose Change

Objective To describe clinical effectiveness of belimumab for systemic lupus erythematosus (SLE) in real-world practice in Argentina. Methods This retrospective, observational study analysed medical record data of patients with SLE treated with belimumab in 15 centres in Argentina. Primary endpoint: overall clinical response (assessed on a scale similar to the 6-point Physician Global Assessment) at months 6, 12, 18 and 24, all versus index (belimumab initiation). Secondary endpoints: improvement in disease activity (SELENA-SLEDAI), SLE manifestations, and corticosteroid dose change. Results Records for 81 patients (91% female) were analysed. Clinical improvements were reported for 95%, 95%, 98% and 100% patients at 6, 12, 18, and 24 months post index, respectively. Mean SELENA-SLEDAI score decreased from 11.21 at index to 4.76, 3.77, 3.86 and 2.17 at 6, 12, 18, and 24 months post index, respectively. Number of flares decreased from 1.05 at index to 0.21, 0.09, 0.22 and 0.30 at 6, 12, 18, and 24 months post index, respectively. Mean corticosteroid dose was 14.59 mg/day at index, and 6.45, 5.18, 5.17 and 4.78 mg/day at 6, 12, 18, and 24 months post index, respectively. Conclusions Real-world patients with SLE treated with belimumab in Argentina demonstrated clinical improvements and reductions in corticosteroid dose.

scholarly journals A Real-World Characterization of Patients With “Moderate-To-Severe” Systemic Lupus Erythematosus

2014 ◽  
Vol 17 (7) ◽  
pp. A522
Author(s):  
V. Strand ◽  
J. Johnson ◽  
C. Vandeloo ◽  
C. Galateanu ◽  
S. Lobosco
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Real World ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Severe Systemic Lupus Erythematosus

Laboratory investigation results influence Physician’s Global Assessment (PGA) of disease activity in SLE

2020 ◽  
pp. annrheumdis-2019-216753 ◽  
Author(s):  
Cynthia Aranow ◽  
Anca Askanase ◽  
Shereen Oon ◽  
Molla Huq ◽  
Alicia Calderone ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Global Assessment ◽  
Intraclass Correlation ◽  
Physician Global Assessment ◽  
Systemic Lupus ◽  
Laboratory Test Results ◽  
Laboratory Results ◽  
The Impact

ObjectiveTo evaluate the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus erythematosus.MethodsFifty clinical vignettes were presented via an online survey to a group of international lupus experts. For each case, respondents scored the PGA pre and post knowledge of laboratory test results (pre-lab and post-lab PGAs). Agreement between individual assessors and relationships between pre-lab and post-lab PGAs, and PGAs and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) were determined. Respondents were also asked about factors they incorporate into their PGA determinations.ResultsSixty surveys were completed. The inter-rater PGA reliability was excellent (pre-lab intraclass correlation coefficient (ICC) 0.98; post-lab ICC 0.99). Post-lab PGAs were higher than pre-lab PGAs: median (IQR) pre-lab PGA 0.5 (1.05), post-lab PGA 1 (1.3) (p<0.001), with a median (IQR) difference of 0.2 (0.45). In general, all abnormal labs including elevated anti-double stranded DNA antibody level (dsDNA) and low complement impacted PGA assessment. Cases with weakest correlations between pre-lab and post-lab PGA were characterised by laboratory results revealing nephritis and/or haematological manifestations. Both pre-lab and post-lab PGAs correlated with SLEDAI-2K. However, a significantly stronger correlation was observed between post-lab PGA and SLEDAI-2K. Multiple factors influenced PGA determinations. Some factors were considered by an overwhelming majority of lupus experts, with less agreement on others.ConclusionsWe found excellent inter-rater reliability for PGAs in a group of international lupus experts. Post-lab PGA scores were higher than pre-lab PGA scores, with a significantly stronger correlation with the SLEDAI-2K. Our findings indicate that PGA scoring should be performed with knowledge of pertinent laboratory results.

SAT0311 The Comparability of Patient and Physician Global Assessment in Early and Non-Early Systemic Lupus Erythematosus Patients

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 780.2-780
Author(s):  
M. Pasali ◽  
V. Sadovici-Bobeica ◽  
M. Cebanu ◽  
V. Salaru ◽  
L. Mazur-Nicorici ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Global Assessment ◽  
Physician Global Assessment ◽  
Systemic Lupus

scholarly journals Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada

2018 ◽  
Vol 38 (9) ◽  
pp. 1721-1726 ◽  
Author(s):  
Francis Fatoye ◽  
Tadesse Gebrye ◽  
Lawrence W. Svenson
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Real World ◽  
Lupus Erythematosus ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document